Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FJQC4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg on December 30, 2025. This firm fixed-price delivery order represents a specific pharmaceutical procurement under the company's existing contract vehicle. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order will be fulfilled at the contractor's Park Ridge location with an ultimate completion date of December 31, 2025.
This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to support recurring medical supply needs across Department of Defense healthcare facilities worldwide. The parent contract, valued at $499.999 billion with a completion date of December 31, 2036, establishes DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply branded and generic prescription drugs, biologics, and medical consumables to military medical facilities globally. This specific delivery order for Xtandi, an oncology treatment, reflects the contractor's demonstrated capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system through numerous prior successful deliveries across multiple therapeutic categories.
Quick answers
Who was awarded contract SPE2DR26FJQC4?
SPE2DR26FJQC4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FJQC4 worth?
The government has obligated $4,255 on SPE2DR26FJQC4.
Is contract SPE2DR26FJQC4 an order under another contract?
Yes. SPE2DR26FJQC4 is a delivery order under SPE2DR25D9224, an indefinite delivery contract.
Was contract SPE2DR26FJQC4 competed?
The extent of competition for SPE2DR26FJQC4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award